Call for Abstracts
_Submission Criteria

1. Solely abstracts not yet published as a manuscript are allowed for presentation at the Conference.

2. Summaries of new research protocols, ongoing research (with partial results), and updated research in the area of Lung Cancer will be acceptable for submission and presentation.

3. At the time of abstract submission, all co-authors must be declared and no later co-author inclusion is acceptable after submission. The presenter author and the corresponding author should also be identified.

4. Presenters and corresponding authors must be registered as participants in the Conference.

5. The submission implies that the abstract will be presented at the Conference if selected, as well as that the Presenter will be available during the scheduled time of Poster Session.

6. Submissions of Abstracts are made online as indicated at the Web Site, and upon registration. Abstracts are due on June 20th, 2008. Please send a copy of the Abstracts submitted online by e-mail, in Word for Windows, to Mrs. Sandra Galeotti (e-mail: galeotti@iaslc-lalca2008.com).

7. The corresponding author will receive all future correspondence from the Abstract Program Committee.
_Author Responsabilities

1. An appropriate ethics committee or the institutional review board must approve abstracts on clinical research and, when informed consent is an ethical requirement, the corresponding author must verify that such was obtained for all subjects included in the study.

2. Corresponding authors must ascertain that all co-authors are aware of the contents of the abstract and support its data.

_Submission Guidelines

Submission of the abstract should be done in two-page format. The 1st. page is the Submission Form, which should include the follow items:

1. Abstract Title, with the first letter of each major word of the title capitalized.

2. Authors names, listed by the first name, middle initial, and last name (e.g. Able B. Care, Barbara C. Doolittle, and David Ford).  No titles or degrees should be included.

3. Authors’ institutional affiliation. Capitalize each major word.  For those abstracts that represent collaborative efforts, list the department/division, school, and/or other organizational affiliation in the order that corresponds with the order of the authors.

4. Corresponding author information: name, address, telephone number, fax number, and e-mail address of the Corresponding Author.

5. Presentation type preferred. Assignment of the final form is at the discretion of the Abstract Program Committee.

6. Tumor Type and Related Conditions (select from list below). Final categorization is at the discretion of the Abstract Program Committee.

7. Topic Category (select from list below). Final categorization is at the discretion of the Abstract Program Committee.

8. A written statement as follows: “The corresponding author declares that this submitted abstract does not contain any copyright violation in its material nor is using in posters any table or drawings by third parts without their written authorization.”

9. A written statement as follows: “The corresponding author declares that information provided in the present abstract is complete and accurate for all of the authors, being submitted with the knowledge and consent of all the listed co-authors.”

The 2nd page is the Abstract Form, which should follow the guidelines below:

1. Abstracts should be prepared using 12 point Times New Roman font in single-line spacing.

2. The body of the abstract (not including title, authors and institutional affiliation) should not exceed 350 words.

3. The abstract is required to follow a coherent structural sequence:  Aim; Background; Material and Methods; Results; Discussion, Conclusions; Bibliographic References). However, text does not need to be divided in sections, and not all sections may be pertinent.

4. Acknowledgement to grants may be inserted before bibliographic references.

5. A minimum of four and maximum of six key words must accompany the abstract.

6. Drugs must be cited solely by their generic names and no brand names are acceptable.

7. Up to three tables can be included provided they are sent on separate files, along with the respective legends.

8. Illustrations are not acceptable on the abstracts.

_Lung Tumor Types

1. Non-Small Cell Lung Cancer (NSCLC)
2. Small Cell Lung Cancer (SCLC)
3. Neuroendocrine Tumor
4. Adenocarcinoma
5. Pancoast Tumor
6. Mesothelioma
7. Carcinomatous Pleural Disease
8. Metastasis
9. Pleural Effusion
10. Bronchial Obstruction
11. Pre-Malignant Lesions
12. Thymic Tumor
_Topic Categories

1. Basic Research
2. Clinical Research
3. Diagnosis Techniques
4. Bronchial or Pulmonary Surgery
5. Clinical Epidemiology and Environmental Carcinogens
6. Anti Smoke Educational Strategy
7. Anticancer Drug Development
8. Public Health Cancer Prevention Policies
_Presentation

Poster Sessions

a. For abstracts selected for poster presentation, presenter authors are required to be available throughout the poster session to answer questions from attendees.

b. Posters must have the following maximum dimensions: 180 cm (Width) per 90 cm (Height).

c. Illustrations on poster must have their authorship clearly stated, if originated from a third part not listed as a co-author.
_Merit Awards

Two Best Abstracts in each Category will be selected for IASLC Merit Certification.
_Feedback

1. Corresponding Authors will receive an e-mail notification from the Abstract Program Committee regarding its decision by mid-August, 2008.

Authors shall bring the poster(s) of the approved abstracts to the LALCa 2008´s reception/secretariat, on the first day of the Conference, where further instructions will be available.
_Certificates

Only one certificate will be issued per selected Abstract to the Senior Author, displaying the names of all the co-authors.